ΩTB® is a
Universal Drug
Resistance Test for TB

A single test for simultaneous evaluation of all resistance markers, as well as the differentiation between mixed infection, relapse and reinfection

TB and it’s global impact

India accounts for 2.7 million cases out of 10 million cases across the world.

  • India 27%
  • Rest 33%
  • China 9%
  • Indonesia 8%
  • Philippines 6%
  • Pakistan 6%
  • Nigeria 4%
  • Bangladesh 4%
  • South Africa 3%
World map
INDIA
27%
PAKISTAN
6%
CHINA
9%
NIGERIA
4%
BANGLADESH
4%
INDONESIA
8%
PHILIPPINES
6%
SOUTH
AFRICA
3%
REST
33%

Comparing ΩTB® (Omega TB) with current tests

Drug AnalysisAntibiotic Coverage
ΩTB®
18 antibiotics including bedaquiline and delamanid
Culture Test
13 - 15 antibiotics
CBNAAT
1 - 2 antibiotics
LPA
Targeted for first line or second line

ΩTB® Assessment Profile

omega-tb-assessment-profile
  1. Test 18 antibiotics
  2. Specificity: 99.8%
  3. Sensitivity: 85-98%
  4. Phylogenetic reconstruction
  5. Identify mixed infection and coinfections including NTM/MOTT
  6. Strain Information

Benefits of ΩTB®

Comprehensive

Comprehensive

DR profile of 18 drugs, Mixed infections and Co-infections incl NTM

Validated

Validated

Tested and validated on >10,000 genomes and >1000 clinical samples

Accurate

Accurate

High sensitivity and specificity comparable to molecular methods

Affordable

Affordable

Test cost less than or comparable to culture testing

Testimonials

Research Papers